Philadelphia, PA - Olfactory Biosciences Corp. (OLFC) the makers of NOXO Autism Aid(TM) announce today the success of their innovative Autism balm. NOXO's solution provides unprecedented hope for families isolated by behavioral issues related to sensitivities and overstimulation in children with Autism.
NOXO stops the frequency of behavioral issues that trouble children with sensitivities by stopping irritant odors and inducing a calming effect. Providing relief to the overstimulated child and allowing families to enjoy public settings with fewer worries.
NOXO Autism Aid(TM) is similar to a lip balm but is applied just below the nostrils on the upper lip. Allowing the natural formula to be inhaled and take effect. NOXO’s solution is safe, easy to apply and non-invasive. It works on your body’s natural processes and responses. It is the first product to address behavioral issues triggered by sensitivities.
A parent seeking help, Allan Chang, shares his experience with NOXO Autism Aid(TM), "Just like any father, I tried many types of treatment . . . , but to no avail. What attracted me with the NOXO Autism balm is that it is a topical application. I can easily apply it with no power struggle with him. It's been 10 days now and I am in disbelief how this product brought some tranquility in our home. My son is calmer and quieter and his behavioral issues are now down to 10%. I am a Registered Nurse, Theory Instructor and before I decided to have this product, I carefully studied the mechanism of action of this product. Since this product is a "sensory aid", it can also be applied to children or adults with ADD, ADHD, Down syndrome, fragile X, prematurity, and fetal alcohol syndrome who manifest behavioral issues."
Allan A. Chang, RN, BSN, PHN, MSNEd, MSHCM, CCHP
You can get more information on NOXO Autism Aid(TM) at www.noxoinfo.com/autism.html
About Olfactory Biosciences Corp
Olfactory Biosciences Corp.'s NOXO division is focused to develop a variety of products targeting Olfactory Receptors for the desired effect. These alternative medicine wellness products may modify behavior or provide relief to common behavior challenges such as anxiety, smoking or weight control, as examples.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements by the Company, statements regarding the NOXO product line, optimism related to the business, expanding ales and other statements in this press release are forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Such statements are based on current expectations, estimates and projections about the Company's business. Words such as expects, anticipates, intends, plans, believes, sees, estimates and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks and uncertainties that are difficult to predict. Actual results could vary materially from the description contained herein due to many factors including continued market acceptance of the Company's products or the need to raise additional capital. In addition, actual results could vary materially based on changes or slower growth in the indoor garden market; the potential inability to realize expected benefits and synergies; domestic and international business and economic conditions; changes in customer demand or ordering patterns; changes in the competitive environment including pricing pressures or technological changes; technological advances; shortages of manufacturing capacity; future production variables impacting excess inventory and other risk factors listed from time to time in the Company's Securities and Exchange Commission (SEC) filings under "risk factors" and elsewhere. The forward-looking statements contained in this press release speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release.
Richard Stevenson, President
Olfactory Biosciences Corp.
333 E. Lancaster Ave. Suite 317
Wynnewood, PA 19096, USA
Source: Olfactory Biosciences Corp.